This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Growing industry confidence drives shift in digital strategy for clinical trial sponsors PALO ALTO, Calif.–(BUSINESS Traditionally, the prudent lifesciences industry purchases novel technology incrementally at the study level. –(BUSINESS WIRE)– Medable Inc. ,
By simulating trials at scale, QuantHealth’s platform can lower risks, expedite, and optimize drugdevelopment. QuantHealth is already working with several global pharmaceutical companies to use its product in clinical trial design and development. Petra Jantzer, Ph.D., Originally announced January 8th, 2024
In total, Aignostics has now raised over $55 million , reflecting investors’ confidence in its differentiated AI models and clear commercial strategy. About ATHOS With its heritage in healthcare and lifesciences, ATHOS is a single-family office that supports entrepreneurs to positively impact health and well-being.
The new company aims to leverage its extensive data sets and technology to provide innovative solutions across various healthcare sectors, including lifesciences, provider, imaging, health plan, employer, and government health and human services. Subscribe Today! In 2011, the Jeopardy!-winning Subscribe Today!
As part of the partnership, SSI will expand Koneksa’s medical strategy division, especially in translational and clinical drugdevelopment. Koneksa clients gain access to a team of PhDs and MDs at SSI with expertise in drugdevelopment. Learn more at koneksahealth.com.
With long-term backing from AstraZeneca and strategic collaborations with Parexel and Fortrea, Evinova offers globally-scaled digital products and services to the lifesciences and healthcare sector. However, they are vital to the drugdevelopment and approval process and critical in enabling access to innovative medicines.
That is the opinion of Ron Emerson, RN, global healthcare lead at Zoom, as he looks ahead at what he believes will be some developments in healthcare in 2022. You predict that decentralization will become a major theme for health and lifescience organizations. Please elaborate.
Deerfield invests across the lifescience, medical device, diagnostic, digital health, and health service industries at every stage of evolution. The company will use this new funding to further expand its real-world data platform and services in order to drive more efficient and inclusive drugdevelopment in oncology.
Furthermore, by fostering connectivity and automating tasks, DHTs reduce administrative burdens, accelerate recruitment, and improve overall trial transparency, ultimately contributing to faster and more reliable drugdevelopment.
Founded in 2018 and supported from the outset by LallianSe, the lifesciences integrator, BrainTale has developed and commercializes an accessible, reliable and clinically validated brain measurement digital platform solution for drugdevelopers and physicians – neurologists, neuroradiologists and intensivists.
Jane Reed, Director of LifeSciences at Linguamatics, an IQVIA company Pharmaceutical developers have always prioritized drug safety. Discussions will focus on the nuanced packaging and delivery requirements for MABs, emphasizing the commitment to safety standards while ensuring the drugs’ effectiveness.
QuantHealth bridges these gaps by simulating trials at scale, to expedite, derisk, and optimize drugdevelopment. This decline is happening at a time when the need for efficient drugdevelopment has never been greater. This happens because there are major gaps in the research needed to support clinical trials.
.” Prognos Health’s platform is used by over 70 lifesciences customers to accelerate the development of new drugs, improve the safety and efficacy of existing drugs, and identify new patient populations that may benefit from specific treatments.
Their expertise in company building, capital formation, and drugdevelopment will be a tremendous resource to Avilar as the innovation leader in the new field of extracellular protein degradation.” Find out more: www.sanofiventures.com.
Mountain Group Partners’ investment strategy has always focused squarely on supporting companies like AngelEye Heath that are developing transformational technologies that improve the lives of others,” said Byron Smith , Managing Director at Mountain Group Partners. About Mountain Group Partners. About SeedtoB.
Visit [link] HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. link] HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Subscribe Today!
The WHO and the India G20 presidency emphasised its importance by launching ‘The Global Initiative of Digital Health’ (GIDH) in August, proclaiming: “Digital health is a proven accelerator to advance health outcomes and achieve Universal Health Coverage and health-related Sustainable Development Goals.”
AI capabilities will become a critical differentiator, with companies that successfully implement AI solutions gaining significant advantages in drug discovery and development speed, cost reduction, and market intelligence. It’s not just a trend, but a reality we fully expect will accelerate in the coming year.
The seed round was co-led by Wellington Partners and Forbion and includes non-dilutive financing from BMBF GO-Bio, a prestigious German government initiative aimed at supporting the most innovative startups in the lifesciences. Forbion invests in lifesciences companies that are active in the (bio) pharmaceutical space.
The majority of healthcare and lifesciences executives (82%) want to see their organizations more aggressively adopt AI technology, according to a new survey from KPMG, an audit, tax and advisory services firm. However, lifesciences companies seem to be struggling to select the best AI technologies, according to 73% of executives.
Jesse Cugliotta, Global Industry GTM Lead, Healthcare & LifeSciences at Snowflake. One of the core issues is that the industry has become single threaded in its sourcing strategy. Additionally, AI-powered platforms will be prioritized to accelerate the process of drug research and development.
and Director of Clinical Strategy at Particle Health I believe a huge place where generative AI will be able to gain traction in healthcare in 2024 is in developing operational workflows and clinical pathways for resource allocation to specific patient cohorts. Carolyn Ward, M.D.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content